Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10271622 | 0.78 | ESR1 (0.30) | — | |
| SCHEMBL20012987 | 0.76 | MTNR1A (0.40) | TP53 | |
| SCHEMBL15779721 | 0.76 | — | — | |
| SCHEMBL23075009 | 0.76 | — | — | |
| SCHEMBL7335665 | 0.76 | CCR1 (0.31) | — | |
| SCHEMBL10058005 | 0.74 | NOS3 (0.32) | — | |
| SCHEMBL21448971 | 0.74 | LMNA (0.35) | TP53 | |
| SCHEMBL16884340 | 0.72 | KDM4E (0.41) | KDM4E | |
| SCHEMBL24302101 | 0.72 | — | — | |
| SCHEMBL16018759 | 0.72 | HTR2C (0.36) | TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6667404-B2 | Carbamylation of 1-amino group of 1,4-amino-3-hydroxybutane derivative with an organocarbonate containing thiazolyl, oxazolyl, isoxazolyl or isothiazolyl substituent | ABBOTT LABORATORIES | 2003-12-23 | — | — | US | disclosed |
| US-20030195362-A1 | Retroviral protease inhibiting compounds | KEMPF DALE J (US) | 2003-10-16 | — | — | US | disclosed |
| EP-1302468-A1 | Processes and intermediates for manufacturing retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2003-04-16 | — | — | EP | disclosed |
| US-6531610-B1 | Intermediate acylating carbonate | ABBOTT LABORATORIES | 2003-03-11 | — | — | US | disclosed |
| EP-1090914-B1 | Retroviral protease inhibiting compounds | ABBOTT LAB (US) | 2003-01-02 | — | — | EP | disclosed |
| EP-1090914-A2 | Processes and intermediates for manufacturing retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2001-04-11 | — | — | EP | disclosed |
| US-6150530-A | AMIDATION OF AMINE WITH ACID | ABBOTT LABORATORIES (US) | 2000-11-21 | — | — | US | disclosed |
| US-6017928-A | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2000-01-25 | — | — | US | disclosed |
| US-5990135-A | FOR TREATING A RETROVIRAL INFECTION SUCH AS HIV INFECTION; FOR EXAMPLE 5S-N-((2-PYRIDINYL)METHOXYCARBONYL)VALINYLAMINO-2-((N-3 -PYRIDINYL)METHOXYCARBONYL)AMINO-4S-HYDROXY-1,6-DIPHENYL-2-AZAHEXANE AND OTHER COMPOUNDS OF GIVEN FORMULA | ABBOTT LABORATORIES (US) | 1999-11-23 | — | — | US | disclosed |
| US-5892052-A | Process for making retroviral protease inhibiting compounds | ABBOTT LABORTORIES (US) | 1999-04-06 | — | — | US | disclosed |
| EP-0727419-A2 | Retroviral protease inhibiting compounds | Abbott Laboratories (US) | 1996-08-21 | — | — | EP | disclosed |
| US-5541206-A | TREATING HUMAN IMMUNODEFICIENCY VIRUS INFECTION | ABBOTT LABORATORIES (US) | 1996-07-30 | — | — | US | disclosed |
| US-5539122-A | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1996-07-23 | — | — | US | disclosed |
| EP-0683772-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1995-11-29 | — | — | EP | disclosed |
| EP-0674513-A4 | — | — | 1995-10-25 | — | — | EP | disclosed |
| US-5461067-A | For HIV infections | ABBOTT LABORATORIES (US) | 1995-10-24 | — | — | US | disclosed |
| EP-0674513-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS. | ABBOTT LAB (US) | 1995-10-04 | — | — | EP | disclosed |
| EP-0683772-A4 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS. | ABBOTT LAB (US) | 1995-09-27 | — | — | EP | disclosed |
| WO-1994019332-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1994-09-01 | — | — | WO | disclosed |
| WO-1994014436-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1994-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195362-A1 | Retroviral protease inhibiting compounds | PREP, SERPINB1, PRSS1 | KDM4E 1997/4885TP53 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.